Printer Friendly

ENDOTRONICS, INC. CONFIRMS SCIENTIFIC ADVISORY BOARD FOR BIO-ARTIFICIAL LIVER PROJECT

 MINNEAPOLIS, Dec. 15 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) today announced that a distinguished group of respected scientists have been confirmed as members of its Scientific Advisory Board which will guide its Bio-Artificial Liver ("BAL") project. The Advisory Board consists of medical professionals and scientific personnel from outside the University of Minnesota that specialize in liver diseases, liver cell culture and medical device technology. The Advisory Board will provide counsel on scientific aspects of the BAL project, overseeing protocols and setting objectives for clinical trials. Activity levels have increased relating to preclinical studies such as performance evaluations and device testing, an important step leading to human clinical trials.
 Dr. Frank B. Cerra, the principal investigator of the BAL project at the University of Minnesota, said: "This Advisory Board is a world- class group of scientists with expertise in liver diseases. We are planning semi-annual reviews with the Advisory Board and look forward to developing a very close working relationship. Their expertise is important to the overall success of the BAL project."
 Richard E. Sakowicz, president and chief operating officer of Endotronics, Inc., said: "Our ability to recruit such a well-renowned group of scientists is a testimonial to this high-quality project. The company would like to recognize members of its BAL Scientific Advisory Board."
 The Board members include:
 -- Nancy L. Ascher, M.D., Ph.D., University of California, San Francisco, professor, Department of Surgery, and chief, Division of Liver Transplantation
 -- Dwight Montgomery Bissell Jr., M.D., University of California, San Francisco, professor of medicine and director, Rice Laboratory, UCSF Liver Center
 -- Mitchell P. Fink, M.D., Harvard Medical School, associate professor of surgery and director, Surgical Critical Care Services, Massachusetts General Hospital
 -- Douglas R. LaBrecque, M.D., University of Iowa, professor, Department of Internal Medicine and director of Liver Services
 -- Robert M. Nerem, Ph.D., Georgia Institute of Technology, Parker H. Petit Distinguished Chair for Engineering in Medicine, George Woodruff School of Mechanical Engineering, and professor, Department of Medicine (adjunct) at the Emory University School of Medicine.
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized industry leader in mammalian cell culture instrumentation with more than 880 instruments installed worldwide.
 -0- 12/15/92
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Endotronics, Inc., 313-871-7350/
 (ENDO)


CO: Endotronics, Inc. ST: Minneapolis IN: MTC SU:

JG -- DE009 -- 7142 12/15/92 11:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 15, 1992
Words:412
Previous Article:FUTUREVISION TO OFFER VIDEO SERVICESOVER ADVANCED BELL NETWORK IN NEW JERSEY
Next Article:IRS LOWERING TAX BURDEN THROUGH SYSTEM REDESIGN
Topics:


Related Articles
UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE
CELOX CORPORATION FILES TRADEMARK SUIT AGAINST FORMER ENDOTRONICS
REGENEREX, INC. APPOINTS PRESIDENT, COO TO LEAD DEVELOPMENT PROGRAM FOR ARTIFICIAL LIVER
Vital Therapies reports significant results in its bioartificial liver trial in China.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters